Summary
Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world.
Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector.
The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.
Read Complete Report with TOC: http://www.radiantinsights.com/research/optina-macular-edema-and-macular-degeneration-forecast-and-market-analysis-to-2023
Optina is an orally-administered, ultra-low-dose capsule reformulation of the steroid danazol that is in Phase III of clinical development by Ampio Pharmaceuticals for the treatment of DME. An effective non-surgical drug treatment for DME is a high unmet need, and Optina is the only drug in late-phase development addressing this need.
Scope
- Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Optina including product description, safety and efficacy profiles...